Want to see AMLX full AI Analyst Report?
AMLX Stock Chart & Stats
$18.41
$0.82(4.66%)
At close: 4:00 PM EDT
$18.41
$0.82(4.66%)
Day’s Range― - ―
52-Week Range$7.48 - $24.60
Previous CloseN/A
Volume1.63M
Average Volume (3M)1.63M
Market Cap
$2.26B
Enterprise Value$1.26K
Total Cash (Recent Filing)$250.76M
Total Debt (Recent Filing)$5.25M
Price to Earnings (P/E)―
Beta1.47
Next Earnings
Nov 05, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.41
Shares Outstanding111,186,320
10 Day Avg. Volume1,486,119
30 Day Avg. Volume1,634,548
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)3.74
Price to Sales (P/S)0.00
P/FCF Ratio-9.25
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$28.43Price Target Upside54.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.47
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Pivotal Phase III Readout & NDA ReadinessAn imminent, conservatively powered pivotal readout and active NDA/launch preparation materially de-risk the path to commercialization. A positive outcome would create a durable revenue engine and shift the business from R&D to commercial execution, altering funding and margin dynamics.
Disease Recognition And Addressable MarketFormal ICD-10 coding and a defined ~160k prevalent U.S. patient base support sustained diagnosis, reimbursement, and market planning. This structural recognition improves long-term patient identification and commercial targeting even if initial label is narrower.
Low Leverage And Multi-year Cash RunwayA sizable cash balance coupled with very low debt (debt-to-equity ~1–2%) gives the company funding visibility to manage the LUCIDITY readout, potential NDA and a 2027 launch. This reduces near-term dilution risk and supports execution of commercial scale-up if approved.
Bears Say
Absent Revenue And Persistent Cash BurnWith effectively no recurring revenue and sizable multi-year net losses, the company remains dependent on trial outcomes or financing to achieve self-sustaining cash flow. Persistent negative FCF implies structural funding needs until commercial revenues materialize.
Manufacturing Commitments And Contingent CostsBinding CMO payment commitments and potential capacity expansion after a positive readout create discrete cash obligations. These contingent manufacturing costs can strain liquidity and margins during scale-up, increasing execution and funding risk post-approval.
Rising SG&A And Unspecified Legal ChargeMaterial increases in SG&A as the company builds commercial capabilities, combined with an unspecified legal charge, elevate near-term cash burn. Higher structural operating costs ahead of revenue generation worsen runway sensitivity and reduce margin flexibility.
Amylyx Pharmaceuticals Inc News
AMLX FAQ
What was Amylyx Pharmaceuticals Inc’s price range in the past 12 months?
Amylyx Pharmaceuticals Inc lowest stock price was $7.48 and its highest was $24.60 in the past 12 months.
What is Amylyx Pharmaceuticals Inc’s market cap?
Amylyx Pharmaceuticals Inc’s market cap is $2.26B.
When is Amylyx Pharmaceuticals Inc’s upcoming earnings report date?
Amylyx Pharmaceuticals Inc’s upcoming earnings report date is Nov 05, 2026 which is in 88 days.
How were Amylyx Pharmaceuticals Inc’s earnings last quarter?
Amylyx Pharmaceuticals Inc released its earnings results on Aug 06, 2026. The company reported -$0.39 earnings per share for the quarter, missing the consensus estimate of -$0.361 by -$0.029.
Is Amylyx Pharmaceuticals Inc overvalued?
According to Wall Street analysts Amylyx Pharmaceuticals Inc’s price is currently Undervalued.
Does Amylyx Pharmaceuticals Inc pay dividends?
Amylyx Pharmaceuticals Inc pays a Quarterly dividend of $0.42 which represents an annual dividend yield of N/A. See more information on Amylyx Pharmaceuticals Inc dividends here
What is Amylyx Pharmaceuticals Inc’s EPS estimate?
Amylyx Pharmaceuticals Inc’s EPS estimate is -0.37.
How many shares outstanding does Amylyx Pharmaceuticals Inc have?
Amylyx Pharmaceuticals Inc has 111,186,320 shares outstanding.
What happened to Amylyx Pharmaceuticals Inc’s price movement after its last earnings report?
Amylyx Pharmaceuticals Inc reported an EPS of -$0.39 in its last earnings report, missing expectations of -$0.361. Following the earnings report the stock price went up 10.709%.
Which hedge fund is a major shareholder of Amylyx Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in AMLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amylyx Pharmaceuticals Inc Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$28.43 (54.42% Upside)
$28.43 (54.42% Upside)
Hedge Fund Trend
Decreased
By 307.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $51.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.1%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
121.80%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
33.65%
Trailing 12-Months
Company Description
Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
AMLX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed clear momentum: a pivotal Phase III (LUCIDITY) nearing top-line readout, active NDA and launch preparations, formal disease recognition via ICD-10 coding, a defined prevalent patient population (~160,000 U.S. patients with ~75% RYGB), and continued pipeline progress (AMX0035, AMX0114, AMX0318). Financially, the company has a solid cash balance with runway into 2028 but experienced a quarter-over-quarter cash decline (~10.4%), rising operating/SG&A costs (SG&A +40.4% YoY), and an unspecified one-time legal charge. Key risks remain: the outcome of the blinded Phase III readout and potential label limitations, early-stage EAP activation constraints, and possible additional manufacturing obligations. Overall the positives (imminent pivotal readout, launch preparedness, market opportunity, and pipeline advancement) outweigh the operational and financial headwinds discussed.View all AMLX earnings summariesAMLX Stock 12 Month Forecast
Average Price Target
$28.43
▲(54.42% Upside)
Technical Analysis
BioCryst
―
Dianthus Therapeutics
―
Harmony Biosciences Holdings
―
Pharvaris
―
Biohaven Ltd.
―
Ownership Overview
8.03% Insiders
24.51% Mutual Funds
0.63% Other Institutional Investors
51.73% Public Companies and
Individual Investors